• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

作者信息

Fukuhara Noriko, Yamamoto Go, Tsujimura Hideki, Chou Takaaki, Shibayama Hirohiko, Yanai Tomoko, Shibuya Kazunori, Izutsu Koji

机构信息

Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

出版信息

Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22.

DOI:10.1080/10428194.2019.1654100
PMID:31437057
Abstract
摘要

相似文献

1
Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.复发/难治性经典型霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者使用本妥昔单抗进行再治疗：一项多中心回顾性研究。
Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22.
2
Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.使用第二代抗体药物偶联物治疗复发或难治性霍奇金淋巴瘤：聚焦于维布妥昔单抗
BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7.
3
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.CD30 阳性血液系统恶性肿瘤患者用 Brentuximab vedotin 再治疗。
J Hematol Oncol. 2014 Mar 19;7:24. doi: 10.1186/1756-8722-7-24.
4
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
5
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.在复发或难治性 CD30 阳性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤的日本患者中进行 brentuximab vedotin 的 I/II 期研究。
Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.
6
Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.贝林妥欧单抗（SGN-35）治疗复发或难治性 CD30 阳性霍奇金淋巴瘤或系统性间变大细胞淋巴瘤的日本儿童的 I 期研究。
Int J Hematol. 2020 May;111(5):711-718. doi: 10.1007/s12185-020-02820-1. Epub 2020 Jan 20.
7
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.维布妥昔单抗治疗儿童复发或难治性霍奇金淋巴瘤及间变性大细胞淋巴瘤：一项多中心、开放标签的1/2期研究。
Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.
8
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.在中国复发/难治性经典型霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者中进行的 brentuximab vedotin 的 II 期单臂研究。
Expert Rev Hematol. 2021 Sep;14(9):867-875. doi: 10.1080/17474086.2021.1942831. Epub 2021 Aug 24.
9
Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.在指定患者计划中，本妥昔单抗治疗复发/难治性霍奇金淋巴瘤及复发/难治性系统性间变性大细胞淋巴瘤的经验：文献综述
Crit Rev Oncol Hematol. 2015 Sep;95(3):359-69. doi: 10.1016/j.critrevonc.2015.03.011. Epub 2015 Apr 27.
10
Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.本妥昔单抗维迪昔单抗：一项在先前治疗失败的霍奇金淋巴瘤和系统性间变大细胞淋巴瘤患者中应用的综述。
Drugs. 2013 Mar;73(4):371-81. doi: 10.1007/s40265-013-0031-5.

引用本文的文献

1
Successful Re-administration and Extended Dosing of Brentuximab Vedotin Monotherapy for Relapsed Anaplastic Large Cell Lymphoma in a Vulnerable Patient.在一名脆弱患者中成功重新给予本妥昔单抗单药治疗并延长剂量用于复发间变性大细胞淋巴瘤
Cureus. 2025 May 13;17(5):e84058. doi: 10.7759/cureus.84058. eCollection 2025 May.
2
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study.复发/难治性CD30+恶性肿瘤患者使用维布妥昔单抗进行再治疗：西班牙的一项回顾性病历审查研究——BELIEVE研究
Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137.
3
Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas.
用本妥昔单抗对不一致的外周T细胞淋巴瘤进行再治疗。
Leuk Res Rep. 2025 Jan 14;23:100500. doi: 10.1016/j.lrr.2025.100500. eCollection 2025.
4
Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study.基于本妥昔单抗的方案治疗系统性间变性大细胞淋巴瘤的真实世界经验：一项多中心回顾性研究。
Front Oncol. 2025 Jan 7;14:1494384. doi: 10.3389/fonc.2024.1494384. eCollection 2024.
5
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.贝林妥欧单抗再治疗复发或难治性经典型霍奇金淋巴瘤或外周 T 细胞淋巴瘤患者：一项回顾性美国理赔分析。
Curr Oncol. 2024 May 2;31(5):2598-2609. doi: 10.3390/curroncol31050195.
6
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.苯达莫司汀联合化疗治疗复发/难治性霍奇金淋巴瘤的倾向评分匹配分析。
Blood Adv. 2024 Jun 11;8(11):2740-2752. doi: 10.1182/bloodadvances.2023012145.
7
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study.贝林妥欧单抗治疗中国淋巴瘤患者的多中心真实世界研究。
Cancer Med. 2023 Dec;12(24):21725-21734. doi: 10.1002/cam4.6733. Epub 2023 Nov 17.
8
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤：现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.
9
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin.用延长疗程的维布妥昔单抗成功治疗血液透析患者的霍奇金淋巴瘤
Case Rep Oncol. 2022 Mar 15;15(1):263-266. doi: 10.1159/000523823. eCollection 2022 Jan-Apr.
10
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.霍奇金淋巴瘤的一线挽救治疗选择：传统化疗与新型药物。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):240-246. doi: 10.1182/hematology.2021000311.